Novavax
NVAX
167 hedge funds and large institutions have $290M invested in Novavax in 2018 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 53 increasing their positions, 41 reducing their positions, and 21 closing their positions.
163% more call options, than puts
Call options by funds: $13.1M | Put options by funds: $4.98M
33% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 21
29% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 41
4% more funds holding
Funds holding: 160 → 167 (+7)
0.01% more ownership
Funds ownership: 2.05% → 2.06% (+0.01%)
2% less capital invested
Capital invested by funds: $295M → $290M (-$4.43M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$5.45M |
| 2 |
Two Sigma Investments
New York
|
+$4.4M |
| 3 |
Millennium Management
New York
|
+$3.19M |
| 4 |
Parallax Volatility Advisers
San Francisco,
California
|
+$1.89M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$5.62M |
| 2 |
RI
RTW Investments
New York
|
-$5.21M |
| 3 |
State Street
Boston,
Massachusetts
|
-$5.15M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.25M |
NVAX Hedge Fund Activity: Q4 2018 in Review
167 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Novavax (NVAX) for Q4 2018, worth a combined $290M — down 1.5% from $295M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new NVAX positions and 21 closed out — a net gain of 7 holders — while 53 added to existing stakes and 41 trimmed.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $5.45M. The largest seller was Pictet Asset Management (UK), exiting entirely with an estimated $5.62M sold.
- 167 institutional investors held Novavax (NVAX) as of Q4 2018, up from 160 in Q3 2018.
- Funds reported $290M of Novavax stock for Q4 2018, down 1.5% quarter-over-quarter.
- 28 funds opened new Novavax positions in Q4 2018 and 21 closed out, a net change of +7 holders.
- The largest Novavax buyer in Q4 2018 was T. Rowe Price Associates, an estimated $5.45M added.
- The largest Novavax seller in Q4 2018 was Pictet Asset Management (UK), an estimated $5.62M sold.
Based on aggregated 13F filings for Q4 2018.